Many forms of epilepsy manifest and/or are diagnosed months or even years after an epileptogenic insult or identification of a genetic defect.Epilepsies that result from an insult or genetic defect could be amenable to secondary prevention but preventive treatments are not available.Development of preventive therapies is complicated by the fact that only a subset of at-risk individuals develop clinical epilepsy.Biomarkers are needed to clearly identify individuals who have the highest risk of developing epilepsy after an epileptogenic insult.We propose a strategic roadmap designed to facilitate the identification, characterization and clinical validation of biomarkers for epileptogenesis.
